Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by French Innovative Leukemia Organisation
Sponsor:
Information provided by (Responsible Party):
French Innovative Leukemia Organisation
ClinicalTrials.gov Identifier:
NCT01795677
First received: December 21, 2012
Last updated: March 15, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)